关键词: 
¹⁸⁸Re /
肝癌H₂₂ /
抗肿瘤 /
内照射剂量 /
组织病理学

摘要: 对建立的肝癌H22荷瘤小鼠实体瘤体局部注射¹⁸⁸Re后， 采用CRCR-15型核素测量仪分别测定1和24 h瘤体内放射性计数， 计算¹⁸⁸Re注入瘤体内24 h内照射吸收剂量以及放射性滞留率。¹⁸⁸Re-S注射至肿瘤内后， 1和24 h放射性药物滞留要高于单纯¹⁸⁸Re注射液， ¹⁸⁸Re-S (0.1 mCi)和(0.2 mCi)组24 h瘤体内照射剂量分别为 159.78和361.52 Gy。病理学检查结果： (1) 模型组, 瘤细胞生长旺盛, 肿瘤内新生微血管丰富; (2) 治疗组, 瘤组织生长受到不同程度的抑制， 瘤细胞生长稀疏， 微血管减少， 坏死区由瘤组织外周向中心渐进。电镜观察显示, ¹⁸⁸Re-S（0.1 mCi）治疗组可见肿瘤组织细胞凋亡小体。将¹⁸⁸Re-S置入小肝癌H22荷瘤小鼠实体瘤局部， 在肿瘤局部形成高活度放射性聚集区， 起到靶向治疗肿瘤作用的同时， 可减少全身用量， 以降低毒副作用。The retention of the radioactive nuclide 188Re in tumor was measured in 1h and 24 h after injection of 188Re and 188ReS, respectively. The results indicate that the radionuclide remained in the tumor injected 188ReS was higher than that in the tumor of injected 188Re. Pathology test results show that in the model group one can find obviously the rapid growth of tumor cells and rich tumor angiogenesis; in the treatment groups the tumor growth is constrained in different degrees, microvascular was less and the necrosis area was spreading from the periphery to the center of the tumor. Scanning the samples of the tumors treated by 0.1 mCi 188ReS injection by using SEM shows there is a lot of apoptotic bodies of tumor cells. The injection of 188ReS into the tumor can be an effective target treatment source for therapy to decrease the radiation dosage in whole body and to reduce the toxicity side effects.